ESMO 2023: Could BioNTech’s BNT211 Break Out Of The CAR-T Solid Tumor Cage?

 
• By Alaric DeArment
  
BioNTech presented data from the Phase I/II trial of BNT211 in solid tumors • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer